DK3188599T3 - Medicinske behandlinger baseret på anamorelin - Google Patents

Medicinske behandlinger baseret på anamorelin Download PDF

Info

Publication number
DK3188599T3
DK3188599T3 DK15838548T DK15838548T DK3188599T3 DK 3188599 T3 DK3188599 T3 DK 3188599T3 DK 15838548 T DK15838548 T DK 15838548T DK 15838548 T DK15838548 T DK 15838548T DK 3188599 T3 DK3188599 T3 DK 3188599T3
Authority
DK
Denmark
Prior art keywords
anamoreline
medical treatments
treatments based
medical
treatments
Prior art date
Application number
DK15838548T
Other languages
English (en)
Inventor
William Mann
William Polvino
Suzan Allen
Ming Lu
John Friend
Elizabeth Duus
Ruben Giorgino
Enrico Baroni
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3188599(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Application granted granted Critical
Publication of DK3188599T3 publication Critical patent/DK3188599T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK15838548T 2014-09-04 2015-08-28 Medicinske behandlinger baseret på anamorelin DK3188599T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (1)

Publication Number Publication Date
DK3188599T3 true DK3188599T3 (da) 2019-11-25

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15838548T DK3188599T3 (da) 2014-09-04 2015-08-28 Medicinske behandlinger baseret på anamorelin

Country Status (44)

Country Link
US (5) US9675600B2 (da)
EP (2) EP3590338A3 (da)
JP (3) JP6356907B2 (da)
KR (3) KR102234319B1 (da)
CN (5) CN113577074A (da)
AP (1) AP2017009772A0 (da)
AR (1) AR103118A1 (da)
AU (1) AU2015312231B2 (da)
BR (1) BR112017003552A2 (da)
CA (1) CA2959158A1 (da)
CL (1) CL2017000494A1 (da)
CO (1) CO2017003263A2 (da)
CR (1) CR20170121A (da)
CY (1) CY1122746T1 (da)
DK (1) DK3188599T3 (da)
DO (1) DOP2017000055A (da)
EA (1) EA035578B1 (da)
EC (1) ECSP17019893A (da)
ES (1) ES2761777T3 (da)
GE (1) GEP20186939B (da)
HR (1) HRP20192345T1 (da)
HU (1) HUE046894T2 (da)
IL (1) IL250692B (da)
JO (1) JO3541B1 (da)
LT (1) LT3188599T (da)
MA (1) MA40607B1 (da)
MD (1) MD4710C1 (da)
ME (1) ME03597B (da)
MX (1) MX361741B (da)
MY (1) MY187167A (da)
NI (1) NI201700024A (da)
PE (1) PE20171109A1 (da)
PH (1) PH12017500392A1 (da)
PL (1) PL3188599T3 (da)
PT (1) PT3188599T (da)
RS (1) RS59751B1 (da)
SG (1) SG11201701567UA (da)
SI (1) SI3188599T1 (da)
SV (1) SV2017005400A (da)
TN (1) TN2017000040A1 (da)
TW (1) TWI639429B (da)
UA (1) UA120765C2 (da)
UY (1) UY36286A (da)
WO (1) WO2016036598A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
BR112017003552A2 (pt) 2014-09-04 2017-12-05 Helsinn Healthcare Sa ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total?
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
CN115569119A (zh) 2019-08-30 2023-01-06 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
WO2021079978A1 (ja) * 2019-10-24 2021-04-29 東レ株式会社 悪液質の治療剤又は予防剤
WO2023042158A1 (en) * 2021-09-17 2023-03-23 Helsinn Healthcare Sa Methods of determining and providing clinically meaningful improvements on patient reported outcomes in anorexia / cachexia patients

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
JP2007523048A (ja) * 2003-08-06 2007-08-16 ガストロテック・ファルマ・アクティーゼルスカブ 分泌促進物質の使用
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
WO2005097261A1 (en) 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
WO2006016995A1 (en) * 2004-06-29 2006-02-16 Sapphire Therapeutics, Inc. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN104470524A (zh) * 2012-05-25 2015-03-25 拉夸里亚创药株式会社 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂
BR112017003552A2 (pt) 2014-09-04 2017-12-05 Helsinn Healthcare Sa ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total?

Also Published As

Publication number Publication date
LT3188599T (lt) 2019-12-10
HRP20192345T1 (hr) 2020-03-20
KR20170047372A (ko) 2017-05-04
CN113577074A (zh) 2021-11-02
EA201790352A1 (ru) 2017-07-31
ES2761777T3 (es) 2020-05-21
AU2015312231A1 (en) 2017-03-23
US9675600B2 (en) 2017-06-13
US10894041B2 (en) 2021-01-19
JP2021080281A (ja) 2021-05-27
HUE046894T2 (hu) 2020-04-28
WO2016036598A1 (en) 2016-03-10
TWI639429B (zh) 2018-11-01
AR103118A1 (es) 2017-04-19
MD4710C1 (ro) 2021-04-30
US20210093627A1 (en) 2021-04-01
UA120765C2 (uk) 2020-02-10
JO3541B1 (ar) 2020-07-05
TW201613587A (en) 2016-04-16
EP3188599B1 (en) 2019-10-02
JP7044918B2 (ja) 2022-03-30
IL250692A0 (en) 2017-04-30
JP2018154655A (ja) 2018-10-04
MX2017002825A (es) 2017-09-28
SG11201701567UA (en) 2017-03-30
PH12017500392B1 (en) 2017-07-17
IL250692B (en) 2019-05-30
EP3188599A1 (en) 2017-07-12
EA035578B1 (ru) 2020-07-09
KR20180085047A (ko) 2018-07-25
NZ729673A (en) 2023-09-29
KR20210035923A (ko) 2021-04-01
US20190175574A1 (en) 2019-06-13
CN107375285A (zh) 2017-11-24
AP2017009772A0 (en) 2017-02-28
UY36286A (es) 2016-02-29
KR102307275B1 (ko) 2021-09-30
EP3590338A3 (en) 2020-03-18
PH12017500392A1 (en) 2017-07-17
MD20170025A2 (ro) 2017-07-31
NI201700024A (es) 2017-07-18
US20240024303A1 (en) 2024-01-25
CA2959158A1 (en) 2016-03-10
GEP20186939B (en) 2018-12-25
EP3188599A4 (en) 2017-10-11
PL3188599T3 (pl) 2020-06-01
US20170296526A1 (en) 2017-10-19
JP2017526695A (ja) 2017-09-14
AU2015312231B2 (en) 2017-10-19
KR101881264B1 (ko) 2018-07-23
RS59751B1 (sr) 2020-02-28
TN2017000040A1 (en) 2018-07-04
MA40607B1 (fr) 2019-11-29
US20160067236A1 (en) 2016-03-10
DOP2017000055A (es) 2017-08-15
US11723902B2 (en) 2023-08-15
US10278964B2 (en) 2019-05-07
ECSP17019893A (es) 2017-05-31
CY1122746T1 (el) 2021-03-12
CN107205389A (zh) 2017-09-26
SV2017005400A (es) 2017-04-20
CN113577073A (zh) 2021-11-02
CN109172575A (zh) 2019-01-11
CO2017003263A2 (es) 2017-07-28
KR102234319B1 (ko) 2021-04-01
JP6923486B2 (ja) 2021-08-18
SI3188599T1 (sl) 2020-02-28
CL2017000494A1 (es) 2017-09-15
MY187167A (en) 2021-09-07
EP3590338A2 (en) 2020-01-08
ME03597B (me) 2020-07-20
JP6356907B2 (ja) 2018-07-11
CR20170121A (es) 2017-07-17
MD4710B1 (ro) 2020-09-30
MX361741B (es) 2018-12-14
PE20171109A1 (es) 2017-08-07
BR112017003552A2 (pt) 2017-12-05
PT3188599T (pt) 2020-01-15

Similar Documents

Publication Publication Date Title
DK3590543T3 (da) Medicinsk forbinding
DK3197354T3 (da) Medicinsk anordning
DK3474804T3 (da) Medicinsk forbinding
DK3231444T3 (da) Ny behandling
DK3203834T3 (da) Hovbehandlingsarrangement
DK3215607T3 (da) Phagterapi
DK3393478T3 (da) Kombinationsterapi
IL250692B (en) Medical treatments based on anamorelin
DK3166473T3 (da) Oftalmoskoper
DK3474803T3 (da) Medicinsk forbinding
DE112015001144A5 (de) Therapievorrichtung
BR112016019480A2 (pt) Cateter seguro
DK2913034T3 (da) Kirurgisk håndstykke
FI20145982A (fi) Potilasalusta
FI10397U1 (fi) Nosturiteline
ES1110205Y (es) Dispositivo pulsimetro
ES1135633Y (es) Dispositivo médico
DK3183264T3 (da) Pegyleringsfremgangsmåde
UA28498S (uk) Катетер фолея
ES1117280Y (es) Pieza Quirúrgica
ES1135431Y (es) Ataud.
TH1501005357A (th) สารประกอบพิแรโซล-เอไมด์ และการใช้ทางการแพทย์ของมัน
ES1141057Y (es) Tejido
UA28875S (uk) Шприц
UA28872S (uk) Шприц